Table 1.
Baseline patients’ characteristics (n = 12).
| Baseline Patients’ Characteristics (n = 12) | n | % | ||
|---|---|---|---|---|
| Left Kidney | n (%) | 6 | 60 | |
| Gender | Female n (%) | 6 | 50 | |
| TNM | T1/T2 | 9 | 75 | |
| T3/T4 | 1 | 8 | ||
| Unknown | 2 | 17 | ||
| Fuhrman Grade | I/II | 7 | 58 | |
| III/IV | 3 | 25 | ||
| Unknown | 2 | 17 | ||
| IMDC | Good/Intermediate | 4/5 | 33/42 | |
| Unknown | 3 | 25 | ||
| Systemic Treatment | Before EUS-RFA | VEGFR-TKI/ICI | 4/0 | 33 |
| During EUS-RFA | VEGFR-TKI/ICI | 1/1 | 8 | |
| After EUS-RFA | VEGFR-TKI/ICI | 3/0 | 25 | |
| No systemic treatment | 7 | 58 | ||
| Other Metastatic Sites During RCC Evolution | None | 7 | 58 | |
| Lung | 5 | 42 | ||
| Brain | 1 | 8 | ||
| Liver | 2 | 17 | ||
| Thyroid | 1 | 8 | ||
| Others | 2 | 17 | ||
| Median Time from Nephrectomy to 1st Metastasis | Years (range) | 11.6 | (0–22.2) | |
| Median Time from Nephrectomy to PM | Years (range) | 13.6 | (0–22.2) | |
| Pancreas as the 1st Metastatic Site | n (%) | 9 | 75 | |
| Symptoms at PM Presentation | None | 9 | 75 | |
| Jaundice | 1 | 8 | ||
| Pain | 2 | 17 | ||
| PM Localization at Presentation | Head | 7 | 33 | |
| Uncus | 4 | 19 | ||
| Body | 6 | 29 | ||
| Tail | 4 | 19 | ||
| Median PM SIZE at Presentation | Millimeters, (range) | 17 | (3–35) | |
| Median Number of PM at Presentation (range) | 1 | (1–4) | ||
| PM Number at Presentation (n, %) | 1 2 3–4 |
58 17 25 |
||
TNM: Tumor Node Metastases Classification, IMDC: International Metastatic RCC Database Consortium International, EUS-RFA: Endoscopic Ultra-Sound guided Radio Frequency Ablation, VEGFR-TKI: Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor, ICI: Immune Check Pont Inhibitor, RCC: Renal Cell Carcinoma, PM: pancreatic metastases.